(Q41974114)

14 October 2017

Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy (English)

1 reference

14 October 2017

15

A F Cashen

1 reference

14 October 2017

14

C N Abboud

1 reference

14 October 2017

G L Uy

1

1 reference

14 October 2017

E J Duncavage

2

1 reference

14 October 2017

G S Chang

3

1 reference

14 October 2017

M A Jacoby

4

1 reference

14 October 2017

C A Miller

5

1 reference

14 October 2017

J Shao

6

1 reference

14 October 2017

S Heath

7

1 reference

14 October 2017

K Elliott

8

1 reference

14 October 2017

T Reineck

9

1 reference

14 October 2017

R S Fulton

10

1 reference

14 October 2017

C C Fronick

11

1 reference

14 October 2017

M O'Laughlin

12

1 reference

14 October 2017

L Ganel

13

1 reference

14 October 2017

J F DiPersio

16

1 reference

14 October 2017

R K Wilson

17

1 reference

14 October 2017

D C Link

18

1 reference

14 October 2017

J S Welch

19

1 reference

14 October 2017

T J Ley

20

1 reference

14 October 2017

T A Graubert

21

1 reference

14 October 2017

P Westervelt

22

1 reference

14 October 2017

M J Walter

23

1 reference

14 October 2017

14 October 2016

1 reference

14 October 2017

1 reference

14 October 2017

31

1 reference

14 October 2017

4

1 reference

14 October 2017

872-881

1 reference

Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents

14 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

Landscape of genetic lesions in 944 patients with myelodysplastic syndromes

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

Clinical and biological implications of driver mutations in myelodysplastic syndromes

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

Clonal diversity of recurrently mutated genes in myelodysplastic syndromes.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

The origin and evolution of mutations in acute myeloid leukemia

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

Clonal architecture of secondary acute myeloid leukemia

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

Mutagenicity of 5-aza-2'-deoxycytidine is mediated by the mammalian DNA methyltransferase

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation fo

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5382101

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

18 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FLEU.2016.282

Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27740633

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27740633

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FLEU.2016.282

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2016.282

1 reference

Dimensions Publication ID

14 October 2017

0 references

1 reference

14 October 2017

PubMed publication ID

27740633

1 reference